1.78
Schlusskurs vom Vortag:
$1.80
Offen:
$1.82
24-Stunden-Volumen:
10,525
Relative Volume:
0.79
Marktkapitalisierung:
$12.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.65M
KGV:
-0.40
EPS:
-4.45
Netto-Cashflow:
$-20.83M
1W Leistung:
+0.56%
1M Leistung:
+19.46%
6M Leistung:
-21.24%
1J Leistung:
-41.64%
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1601 TRAPELO ROAD, WALTHAM, MA
Vergleichen Sie NERV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NERV
Minerva Neurosciences Inc
|
1.78 | 12.59M | 0 | -33.65M | -20.83M | -4.45 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
2020-05-14 | Eingeleitet | BTIG Research | Buy |
2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
2019-09-18 | Eingeleitet | William Blair | Outperform |
2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
2017-09-01 | Eingeleitet | Citigroup | Buy |
2017-03-06 | Fortgesetzt | Jefferies | Buy |
2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World
Citadel Advisors LLC Purchases New Holdings in Jiuzi Holdings, Inc. (NASDAQ:JZXN) - Defense World
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Citadel Advisors LLC - Defense World
Minerva Neurosciences Reports Q1 2025 Earnings and Regulatory Challenges - TipRanks
Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Northern Trust Corp - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at Wall Street Zen - Defense World
Minerva Neurosciences: Q1 Earnings Snapshot - CT Insider
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
NERV's Cash Reserves Decrease by $4.1 Million in Q1 2025 | NERV Stock News - GuruFocus
Minerva Neurosciences Reports First Quarter 2025 Financial Resul - GuruFocus
MINERVA NEUROSCIENCES Earnings Results: $NERV Reports Quarterly Earnings - Nasdaq
Minerva Neurosciences, Inc. SEC 10-Q Report - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Has $285,000 Stock Holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Schizophrenia Market to Witness Significant Growth by 2034 - GlobeNewswire
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - The AM Reporter
CLASS ACTION UPDATE for TILE, NERV and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for BABA, NAK and NERV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Minerva Neurosciences stock hits 52-week low at $1.29 - Investing.com Australia
Minerva Neurosciences stock hits 52-week low at $1.29 By Investing.com - Investing.com South Africa
Major depressive disorder Drugs Market 2034: Clinical Trials, - openPR.com
Minerva Neurosciences regains Nasdaq compliance By Investing.com - Investing.com Australia
Minerva Neurosciences regains Nasdaq compliance - Investing.com India
FINAL DEADLINE ALERT: ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Encourages Minerva Neurosciences, Inc. Investors with Large Losses to Secure Counsel Before Important February 8 Deadline – NERV - Business Wire
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld MedTech
Minerva Neurosciences Reports Improved 2024 Financials - TipRanks
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):